Capricor Therapeutics, Inc. (CAPR) has a consensus analyst rating of Buy, based on 10 analysts covering the stock. Of those, 10 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for CAPR is $47.75, representing a +37.5% upside from the current price of $34.72. Price targets range from a low of $13.00 to a high of $62.00.
